New drug duo tested for Tough-to-Treat lung cancer
NCT ID NCT04227028
Summary
This early-phase study is testing a combination of two drugs, brigatinib and bevacizumab, for patients with a specific type of advanced lung cancer (ALK-positive) that has worsened despite prior targeted therapy. The main goals are to find the safest dose and understand the side effects of using these drugs together. Researchers will also check if the treatment helps shrink tumors and control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC LUNG NON-SMALL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
-
Northwestern University
Chicago, Illinois, 60611, United States
-
Penn State Cancer Institute
Hershey, Pennsylvania, 17033, United States
-
Rush University Medical Center
Chicago, Illinois, 60612, United States
-
University of Colorado Cancer Center
Aurora, Colorado, 80045, United States
-
University of Wisconsin Hospital and Clinics
Madison, Wisconsin, 53792, United States
Conditions
Explore the condition pages connected to this study.